Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.5K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.5K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

2.1K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.1K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

3.0K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
3.0K
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

387
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
387
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

1.9K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
1.9K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

5.5K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precision medicine in mental health: applications, challenges, and recommendations - CORRIGENDUM.

European psychiatry : the journal of the Association of European Psychiatrists·2026
Same author

Effects of neuroinflammation and neurotrophic factors on mental health of people with axial spondyloarthritis.

Brain, behavior, & immunity - health·2026
Same author

One brain, one mind: A joint EPA-EAN leadership perspective on brain health.

European psychiatry : the journal of the Association of European Psychiatrists·2026
Same author

Towards a more inclusive psychiatry: diversity among presenters and participants in the 25th World Congress of Psychiatry.

World psychiatry : official journal of the World Psychiatric Association (WPA)·2026
Same author

Association of inflammation and serum adipocytokines with depression and anxiety burden in axial spondyloarthritis.

Scientific reports·2026
Same author

Precision medicine in mental health: applications, challenges, and recommendations.

European psychiatry : the journal of the Association of European Psychiatrists·2026

Related Experiment Video

Updated: Oct 4, 2025

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

26.0K

Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?

Pavel Mohr1,2, Jirí Masopust3, Miloslav Kopeček1,2

  • 1National Institute of Mental Health, Klecany, Czechia.

Frontiers in Psychiatry
|February 11, 2022
PubMed
Summary

Dopamine receptor partial agonists (DRPAs) like aripiprazole, brexpiprazole, and cariprazine show comparable efficacy for acute schizophrenia. However, individual DRPAs offer distinct benefits across various psychiatric conditions.

Keywords:
antipsychoticsaripiprazolebrexpiprazolecariprazineclinical efficacydopamine partial agonists

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.0K
Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake
11:26

Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake

Published on: September 21, 2017

12.6K

Related Experiment Videos

Last Updated: Oct 4, 2025

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

26.0K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.0K
Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake
11:26

Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake

Published on: September 21, 2017

12.6K

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Medicine

Background:

  • Dopamine receptor partial agonists (DRPAs) represent a novel class of antipsychotics.
  • While sharing a mechanism, DRPAs exhibit variations in pharmacodynamics, pharmacokinetics, drug interactions, and safety profiles.
  • Established efficacy in schizophrenia, but comparative clinical data is limited, with no head-to-head trials.

Purpose of the Study:

  • To assess potential differences in the clinical efficacy of DRPAs (aripiprazole, brexpiprazole, cariprazine).
  • To review and synthesize data from controlled trials, systematic reviews, and meta-analyses on DRPA efficacy.
  • To identify specific therapeutic benefits of each DRPA across various psychiatric disorders.

Main Methods:

  • Systematic review of controlled trials, systematic reviews, and meta-analyses.
  • Analysis of efficacy data, including number needed to treat (NNT) for acute antipsychotic effects.
  • Examination of data across schizophrenia, bipolar disorder, major depression, and other conditions.

Main Results:

  • Acute antipsychotic effects of DRPAs are comparable, with all agents superior to placebo.
  • Cariprazine demonstrated efficacy in reducing negative symptoms of schizophrenia.
  • Individual DRPAs showed specific benefits: aripiprazole (agitation, pediatric use, OCD, tics, ASD), cariprazine (bipolar depression, negative symptoms), brexpiprazole (add-on depression, agitation in dementia).

Conclusions:

  • DRPAs are a heterogeneous group regarding clinical efficacy, despite a shared mechanism.
  • Each DRPA possesses unique therapeutic advantages for specific psychiatric indications.
  • The findings support individualized treatment selection based on patient needs and DRPA profiles.